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estimates
were:
V(mL/kg)=497.

Ke(h-1)=0.232x(CR)

Exp-0.85;
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Conclusion
Weight and serum creatinine are associated with neonatal
amikacin volume of distribution and elimination constant
rate, respectively. The presence of sepsis may decrease
amikacin elimination, although this observation should be
further explored. These results could help to individualize
amikacin dosage for neonates.
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ABSTRACT
Background
Amikacin treatment requires close monitoring of blood
concentrations to increase the probability that levels
achieved are both effective and safe.
Aims
We described population pharmacokinetics parameters of
amikacin in newborns from a Neonatal Intensive Care Unit
with suspected or documented sepsis.
Methods
A nonlinear mixed-effect model approach was used to
analyse the data.
Results
Twenty seven neonates were enrolled. Final parameter

Implications for Practice:
1. What is known about this subject?
Adjusting amikacin doses in neonates, based on population
pharmacokinetics studies, are aimed at increasing the
probability that levels achieved are both effective and safe.
2. What new information is offered in this report?
There are very few population pharmacokinetics studies on
amikacin in neonates. Thus, we estimated amikacin
pharmacokinetic parameters in a new neonate cohort.
3. What are the implications for research, policy, or
practice?
These results can help to individualize amikacin dosage in
neonates and, potentially, to reduce neonatal mortality and
morbidity and to improve treatment of sepsis.

Background
Amikacin (AMK) treatment requires close monitoring of
blood concentrations to increase probability that levels
1,2
achieved are both effective and safe. Dosing can be
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improved by the availability of accurate AMK population
pharmacokinetics (PopPK) parameters in neonates. There
3-6
are very few relevant studies on AMK PopPK in neonates.
The objective of this study was to describe AMK PopPK
parameters in new-borns suffering from neonatal suspected
or documented gram negative sepsis. We evaluated
correlations among AMK PK parameters and patient
covariates, and established a model taking into account
relevant covariates.

Case details
A cohort of patients was prospectively recruited from the
Neonatal Intensive Care Unit of the Garrahan Paediatric
Hospital. Patients were eligible for inclusion if they were
prescribed AMK as per institutional guidelines for the
management of known or suspected gram negative
bacterial infections.
Written informed consent was obtained from the parents or
guardians of 27 newborns to collect and store AMK plasma
concentration information. No extra blood samples were
obtained for the purpose of this report, nor were any drug
doses administered that were not included in the routine
clinical care of patients. Results were processed in an
anonymized manner.

drugs, and sepsis. Sepsis was defined as Systemic
Inflammatory Response Syndrome and/or bacteremia
8
confirmed by blood culture (CDC 2015).
Univariate analysis results were used to define the order
each covariate would be incorporated into the multivariate
model, based on the change of the objective function (ΔOF)
and associated P value, with respect to the base model.
Covariate effects on model parameters were initially
evaluated using a forward analysis and were retained in the
model if the objective function (OF) value was reduced at
least 3.84 units (Chi-square test, p<0.05), followed by a
backwards elimination procedure where each covariate was
independently removed from the full model to confirm its
relevance. An increase in the OFV of >10.9 units (p<0.001)
was required for inclusion in the final model.
Likelihood ratio test, Akaike information criteria, Bayesian
information criteria, goodness-of-fit plots, estimates of the
PK parameters and their clinical relevance were used to
select the most appropriate structural model.
A visual predictive check plot (VPC) was constructed based
on the parameters and random effects (final model).

RESULTS
Blood samples (1ml each) were obtained at peak (i.e., half
an hour after finishing a 30 minute AMK infusion), and at
trough (i.e., immediately prior to the next AMK dose), as per
AMK TDM institutional protocol (AMK ampoules, Fada
Pharma Lab, LIA - Argentina) after fourth dose (at steady
7
state). AMK was measured by fluorescence polarization
immunoassay (Abbott Laboratories, Diagnostics Division,
USA). The lower limit of AMK quantitation (LOQ) was
0.8mg/mL. Coefficients of variation were below 5 per cent
over the entire calibration range (0.8–50μg/mL).
A nonlinear mixed-effect modeling approach was used for
PopPK analysis using a Stochastic Approximation of
Expectation
Maximization
(SAEM)
algorithm
as
implemented in MONOLIX software (V 4.2.2). A onecompartment model best ﬁtted the data, and was
parameterized in terms of elimination rate constant (Ke)
and volume of distribution (V). Proportional error model
was used to describe intraindividual variability. AMK plasma
concentrations below LOQ were rejected.
Covariates tested for correlation with AMK pharmacokinetic
parameters were height, weight, birth weight, post-natal
age, gestational age (GA), post-menstrual age (PMA), serum
creatinine (CR) and creatinine clearance, sex, concomitant

A total of 27 newborn patients (18 males) were enrolled in
the study between 2003 and 2007, and received AMK doses
of 7.5mg/kg once-, twice-, or thrice-daily, or 10mg/kg twice,
or thrice-daily. A total of 50 AMK concentrations were
obtained (troughs: 56 per cent). One trough was below
LOQ.
Characteristics of patients were (expressed as median and
range): weight (kg)=2.65 (1.4-4.0); birth weight (kg)=2.60
(1.5-3.3); height (cm)=48 (37-52); post-natal age (days)=21
(6-58); gestational age (weeks)=37 (28-40); post-menstrual
age (weeks)=40.9 (29-43); CR (mg/dL)=0.49 (0.20-1.84) and
2
CR clearance (mL/min/1.73m )=38 (12.65-77.59) calculated
by Schwartz formula. Fifteen out of the 27 patients were
preterm neonates.
Considerable between-subject variability (BSV) in parameter
estimates of the base model was observed, with a BSV for
AMK V and Ke of 46 per cent and 70 per cent, respectively.
Correction of AMK dose by weight explained 48 per cent of
the BSV in V and was thus incorporated in the model. Mean
population PK parameters after dose normalization by
-1
weight were 0.138 h and 497ml/kg, respectively.
Covariates with significant impact on AMK BSV for Ke
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identified in the univariate analysis included CR, GA, PMA,
sepsis, and ibuprofen concomitant administration. The most
significant covariate related to Ke was CR.
Covariates such as GA (on Ke, ΔOF=-6.13), PMA (on Ke,
ΔOF=-5.49), sepsis (on Ke, ΔOF=-4.88) and concomitant
ibuprofen (on V, ΔOF=-5.75), had a statistically significant
effect in the univariate analysis, but were not retained in
the forward analysis. Analysis of scatterplots and boxplots
of the Ke and V with covariates identified those that most
likely explain BSV. Final model VPC plot and goodness-of-fit
plot showed good predictive performance of the final model
(Figures 1 and 2).
Final parameter estimates were:
-0.85
Ke (h-1) =0.232 x (CR)
V (mL/kg) =497
CR explained 20.1 per cent of the BSV in AMK Ke and the
mean population pharmacokinetic parameters were 0.232
h-1 and 497ml/kg for Ke and V, respectively.

Discussion
A reduction in neonatal mortality and morbidity relies
heavily on the rapid implementation of an effective
treatment of neonatal sepsis, which requires a rational use
9,10
of antibiotics based on solid scientific evidence.
We report the PopPK of AMK for the first time in Latin
American neonates. Parameter estimates from our model
are similar to previous studies in neonate populations from
3–6
Europe. Bleyzac et al. (2001) showed that AMK Ke and V
are dependent on GA, and that differential neonatal renal
maturation is responsible for the wide between-subject
9,11
variability in PK.
Other researchers identified weight as
4
the best predictor of neonatal AMK V. Similarly, we show
the importance of weight on AMK V, and, in univariate
analysis, that CR, GA, PMA and sepsis had a statistically
significant influence on Ke, and concomitant ibuprofen
administration on V. Nonetheless, the only covariate
3
retained in the final model, besides weight, was CR on Ke.
Previous reports in critically ill adult patients showed
12
impaired aminoglycosides clearance. In concordance, we
observed in univariate analysis that sepsis seems to
decrease AMK elimination by 32 per cent, and that
ibuprofen administration was associated to a small decrease
on V. Owing to the limited number of patients in our study
we could not confirm these observations in the final model.
We believe that these observed associations should be
explored in larger studies given the importance and high
frequency of sepsis, and ibuprofen use, in neonates
receiving AMK.

We are aware of the limitations imposed by the small
number of patients in our study. It should be noted that
such studies in the neonatal population are extremely
difficult to carry out, so that even small but very closely
monitored studies such as ours can add important
information relevant to the clinical management of these
patients.

Conclusion
Weight and CR are associated with neonatal AMK V and Ke,
respectively, and should be further evaluated for routine
use in the clinics to guide AMK dosing in this population.
The observed link between sepsis and AMK Ke should be
further explored. Our results could help to individualize
AMK dosage for neonates.
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Figure 1: Visual predictive check (VPC). The figure shows the 90 per cent prediction intervals obtained by simulation using
the final model. The areas are (a) the 90 per cent confidence intervals for the 5th percentile and the 90th percentile and
(b) the median of the simulated data, respectively.

Figure 2: Goodness of fit plots. (A) Observed versus population predicted and (B) observed versus individual predicted
values. Concentrations in μg/mL
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